Global Rho Kinases (ROCKs) Inhibitor Market, By Drugs (Netarsudil, Ripasudil Hydrochloride Hydrate, Fasudil, Others), Indication (Cerebral Vasospasm, Glaucoma and Others), Route of Administration (Oral, topical, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Rho Kinases (ROCKs) Inhibitors Market Analysis and Size
The increasing cancer population and rise in novel treatment-seeking rate can act as a positive indication for the growth of Rho Kinases (ROCKs) inhibitors market. In addition to this, strong research and development activities can also increase the market position. Presently, numerous companies are working in this area, creating a strong pipeline of more than 12 active products.
Data Bridge Market Research analyses a growth rate in the Rho Kinases (ROCKs) inhibitors market in the forecast period 2023-2030. The expected CAGR of Rho Kinases (ROCKs) inhibitors market is tend to be around 6.60% in the mentioned forecast period. The market is valued at USD 61.4 billion in 2022, and it would grow upto USD 102.38 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Rho Kinases (ROCKs) Inhibitors Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drugs (Netarsudil, Ripasudil Hydrochloride Hydrate, Fasudil, Others), Indication (Cerebral Vasospasm, Glaucoma and Others), Route of Administration (Oral, topical, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Kowa Pharmaceuticals America, Inc. (U.S.), Senju Pharmaceutical Co.,Ltd. (Japan), Novartis AG (Switzerland), AERIE PHARMACEUTICALS, INC. (U.S.), Redx Pharma Plc (U.K.)
|
|
Market Opportunities
|
|
Market Definition
Rho kinases (ROCKs) inhibitor is a type of rho-associated protein kinase inhibitor a therapeutics belonging to the serine-threonine family. Their function is to target the small GTP-binding protein Rho network that plays an essential role in regulating cell cycle control. ROCK is recommended to be a therapeutic target in several diseases such as ophthalmic diseases, cardiovascular diseases, neurological disorders, autoimmune diseases, and cancer.
Rho Kinases (ROCKs) Inhibitors Market Dynamics
Drivers
- Growing Prevalence of Cancer
Cancer is one of the leading cause of death worldwide, accounting for around 10 million deaths in 2020. The most common in 2020 was breast cancer, about 2.26 million cases. Breast cancer is the most common type, with 290,560 new cases anticipated in the U.S. in 2022. The next most incident cancers are prostate cancer and lung cancer. There was an expected 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) and almost 10.0 million cancer deaths (9.9 million excluding nonmelanoma skin cancer) occurred in 2020 worldwide. Thus, this factor increases the demand of Rho Kinases (ROCKs), further boosting the market growth.
Opportunities
- Increasing Cases of Glaucoma
Glaucoma is a top cause of irreversible blindness in the U.S. and the world. More than three million Americans are surviving with glaucoma, and 2.7 million people aged 40 years and older are affected by its most common form, open-angle glaucoma. Blindness or low vision affects around 3.3 million Americans age 40 years and above. More than 11 million individuals are expected to be bilaterally blind because of glaucoma in 2020. In the majority of the cases, blindness can be prevented with proper control and treatment. In the U.S., blindness is the third most feared health problem, after cancer and cardiac attacks. In this regard, ROCK inhibitors are used to decrease intraocular pressure, which is found to be beneficial for glaucoma, by smoothening the trabecular meshwork cells of the eye which is critical for the drainage of ocular fluid. Thus, this factor helps in increasing the market growth.
- Growing Healthcare Expenditure And Government Support
The rising incidence of cancer, the growing awareness for the disease and the associated treatment is also enhancing. Numerous government initiatives tend to provide better and more convenient treatments and favourable reimbursement policies that are anticipated to increase the industry growth. Additionally, growing acceptance of advanced therapies is projected to drive the market.
Restraints/Challenges
- High Cost of Treatment
The increasing expenditure related with the medications hinder the market growth. Numerous genetic drugs cost high and people in developing and underdeveloped countries, causing the under treatment of several patients. This impedes the market growth.
This Rho Kinases (ROCKs) inhibitors market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Rho Kinases (ROCKs) inhibitors market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Rho Kinases (ROCKs) Inhibitors Market Scope
The Rho Kinases (ROCKs) inhibitors market is segmented on the basis of drugs, indication, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drugs
- Netarsudil
- Ripasudil Hydrochloride Hydrate
- Fasudil
- Others
Indication
- Cerebral Vasospasm
- Glaucoma
- Others
Route of Administration
- Oral
- Topical
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Rho Kinases (ROCKs) Inhibitors Market Regional Analysis/Insights
The Rho Kinases (ROCKs) inhibitors market is analyzed and market size insights and trends are provided by drugs, indication, route of administration, end-users and distribution channel as referenced above.
The major countries covered in the Rho Kinases (ROCKs) inhibitors market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing a positive growth for Rho Kinases (ROCKs) inhibitors market throughout the forecasted period because of the high incidence rate of glaucoma, increasing awareness and development activities for Rho kinases (ROCKs) inhibitor-based therapeutics. Furthermore, the increasing presence of refined clinical facilities and surge in better treatment seeking rates of patients suffering from the eye disorders is boosting the growth of the market.
Asia-Pacific dominates the market because of the healthy improvement in healthcare infrastructure and huge economic development. Additionally, the healthy improvement in healthcare infrastructure boost the market growth.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Rho Kinases (ROCKs) Inhibitors Market Share Analysis
The Rho Kinases (ROCKs) inhibitors market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Rho Kinases (ROCKs) inhibitors market.
Key players operating in the Rho Kinases (ROCKs) inhibitors market include:
- Kowa Pharmaceuticals America, Inc. (U.S.)
- Senju Pharmaceutical Co.,Ltd. (Japan)
- Novartis AG (Switzerland)
- AERIE PHARMACEUTICALS, INC. (U.S.)
- Redx Pharma Plc (U.K.)
SKU-